Management of tinea capitis in infants and children in the United States: A national survey of pediatric dermatologists.

Autor: Guo L; Chicago Medical School, Rosalind Franklin University, North Chicago, Illinois, USA., Tran J; Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Sun DI; Stritch School of Medicine, Loyola University, Maywood, Illinois, USA., Newton JS; Sanford School of Medicine, University of South Dakota, Vermillion, South Dakota, USA., D'Amiano NM; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Lai J; Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cohen B; Department of Pediatrics and Dermatology, Johns Hopkins University, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2024 Mar-Apr; Vol. 41 (2), pp. 263-265. Date of Electronic Publication: 2024 Feb 11.
DOI: 10.1111/pde.15544
Abstrakt: This study aimed to evaluate the current management of tinea capitis in the United States, specifically focusing on patients aged 0-2 months, 2 months to 2 years, and 2 years to 18 years. An online survey, distributed through the Pediatric Dermatology Research Alliance and the Society of Pediatric Dermatology, revealed the following preferences: fluconazole for those under 2 months, griseofulvin for those aged 2 months to 2 years, and terbinafine for those aged 2 years and older. There exists inter-provider variation in tinea capitis treatment regimens within the pediatric dermatology community.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: